首页 TG治疗(usTGTX)-基本信息

TG治疗(usTGTX)-基本信息

日报更新时间:

周报更新时间:04-18 04:06

行情信息

今开价:38.995

最高价:40.89

成交量:1259124.0

昨收价:39.96

最低价:38.715

最新价:40.135

行情图标
概要信息

中文名称:TG治疗


英文名称:TG Therapeutics


简介:TG Therapeutics, Inc.于1993年注册。TG医疗股份有限公司是一家生物制药公司,专注于创新、具有医学重要性治疗产品的收购、开发和销售,用于癌症和其他缺少治疗手段病症的治疗


电话:1-212-5544484


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

TG Therapeutics是一家生物制药公司,专注于B细胞恶性肿瘤和自身免疫性疾病的新型疗法的收购、开发和商业化。目前,该公司正在开发针对血液系统恶性肿瘤和自身免疫疾病的两种疗法。Ublituximab(TG-1101)是一种新型糖基化改造的单克隆抗体,其靶向成熟B淋巴细胞上发现的CD20抗原上的特异性和独特表位。TG Therapeutics还开发了umbralisib(TGR-1202),一种口服、每日一次的PI3K-delta抑制剂。Umbralisib独特地抑制CK1-epsilon,这可以使其克服与第一代PI3K-delta抑制剂相关的某些耐受性问题。Ublituximab和Umbralisib,或其被称为'U2'的组合,在血液系统恶性肿瘤患者的 III 期临床开发中,Ublituximab也在多发性硬化患者的 III 期临床开发中。此外,TG Therapeutics公司最近推出了抗PD-L1单克隆抗体TG-1501;其共价结合的Bruton酪氨酸激酶(Bruton Tyrosine Kinase,BTK)抑制剂TG-1701;以及其抗CD47 / CD19双特异性抗体TG-1801;目前进入 I 期开发阶段。TG Therapeutics, Inc. 与 LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A; Checkpoint Therapeutics, Inc.; Jiangsu Hengrui Medicine Co.; Novimmune SA; Ligand Pharmaceuticals Incorporated 和 Jubilant Biosys建立战略联盟关系。

交易日期 交易人 职位 类型 交易份额 价格
2017-06-18 Weiss (Michael S) Chief Executive Officer Buy 834877 --
2017-06-18 Power (Sean A) Chief Financial Officer Sell 30000 11.04
2017-06-18 Weiss (Michael S) Chief Executive Officer Gift 350000 --
2017-06-15 Charney (Laurence Neil) Director Buy 15000 --
2017-06-15 Power (Sean A) Chief Financial Officer Sell 29976 11.14
2017-06-15 Kennedy (William James) Director Buy 15000 --
2017-06-15 Schoenebaum (Mark) Director Buy 15000 --
2017-06-15 Hume (Daniel) Director Buy 15000 --
2017-06-15 Hoberman (Kenneth) Director Buy 15000 --
2017-06-15 Echelard (Yann) Director Buy 15000 --
2017-04-10 Kennedy (William James) Director Sell 8548 10.27
2017-04-03 Charney (Laurence Neil) Director Sell 7000 11.17
2017-01-03 Power (Sean A) Chief Financial Officer Sell 8816 4.55
2016-12-31 Weiss (Michael S) Chief Executive Officer Sell 3381866 --
2016-12-31 Weiss (Michael S) Chief Executive Officer Buy 2960000 --
2016-12-31 Weiss (Michael S) Chief Executive Officer Buy 418371 --
2016-12-29 Weiss (Michael S) Chief Executive Officer Buy 693750 --
2016-12-29 Power (Sean A) Chief Financial Officer Buy 100000 --
2016-08-31 Weiss (Michael S) Chief Executive Officer Gift 328764 --
2016-07-05 Kennedy (William James) Director Buy 12459 --
2016-07-05 Charney (Laurence Neil) Director Buy 12459 --
2016-07-05 Schoenebaum (Mark) Director Buy 12459 --
2016-07-05 Echelard (Yann) Director Buy 12459 --
2016-07-05 Hume (Daniel) Director Buy 12459 --
2016-07-05 Hoberman (Kenneth) Director Buy 12459 --
2016-07-04 Power (Sean A) Chief Financial Officer Sell 50426 5.99
2016-04-17 Power (Sean A) Chief Financial Officer Sell 10000 10.12
2016-01-04 Power (Sean A) Chief Financial Officer Sell 22790 11.21
2015-12-30 Power (Sean A) Chief Financial Officer Buy 50000 --
2015-12-30 Weiss (Michael S) Chief Executive Officer Buy 6723443 --

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Highland Capital Management LP 878360 0.97% 425000 93.74% 2019-03-31
BlackRock Fund Advisors 2722269 3.00% 15684 0.58% 2019-07-31
State Street Corporation 3276966 3.61% -1065652 -24.54% 2019-03-31
Vanguard Group Inc 3375742 3.72% 1396074 70.52% 2019-03-31
SSGA Funds Management Inc 3649372 4.02% 72972 2.04% 2019-07-31
Bridger Management LLC 4003481 4.41% 211950 5.59% 2019-03-31
BlackRock Inc 4437891 4.89% -81440 -1.80% 2019-03-31
Millennium Management LLC 4905786 5.40% 4786175 4001.45% 2019-03-31
RA Capital Management, LLC 8198337 9.03% -- -- 2019-03-31
FMR Inc 2402037 2.64% -321400 -11.80% 2019-03-31
Fidelity Management and Research Company 2402037 2.64% -321400 -11.80% 2019-03-31
Vanguard Investments Australia Ltd 2337743 2.57% -68 -- 2019-07-31
Geode Capital Management, LLC 928149 1.02% -582261 -38.55% 2019-03-31
Goldman Sachs Group Inc 940656 1.04% 178071 23.35% 2019-03-31
Northern Trust Investments Inc 1268822 1.40% 40818 3.32% 2019-07-31
Point72 Asset Management, L.P. 1278900 1.41% 1278900 -- 2019-03-31
Calyon 1307428 1.44% -- -- 2019-03-31
Cr¨?dit Agricole S.A. 1307428 1.44% -- -- 2019-03-31
Opaleye Management Inc 1366062 1.50% 816062 148.37% 2019-03-31
Fidelity SelectCo, LLC 2056141 2.26% -221296 -9.72% 2019-07-31
BlackRock Asset Management Canada Ltd 1522046 1.68% -111 -0.01% 2019-05-31
venBio Select Advisor LLC 4750000 5.23% 549969 13.09% 2018-12-31
Great Point Partners LLC 3000000 3.30% 1050000 53.85% 2018-12-31
Northern Trust Corp 801560 0.96% -20879 -2.54% 2018-12-31
Renaissance Technologies Corp 875900 1.04% 523400 148.48% 2018-12-31
Deutsche Bank AG 824164 0.98% 345477 72.17% 2018-12-31
Northern Trust Investments N A 801560 0.96% -20879 -2.54% 2018-12-31
Two Sigma Investments LLC 769011 0.92% 582771 312.91% 2018-12-31
Franklin Resources Inc 1892978 2.26% -391499 -17.14% 2018-09-30
Franklin Advisers, Inc. 1883478 2.25% -380299 -16.80% 2018-09-30
Candriam Luxembourg 692000 0.83% 267000 62.82% 2018-09-30
Candriam Belgium 692000 0.83% 14000 2.06% 2018-11-30
PGIM Investments LLC 938019 1.13% -- -- 2018-11-30
BlackRock Institutional Trust Company NA 1656546 2.00% 106022 6.84% 2018-06-30
UBS Asset Mgmt Americas Inc 696792 0.84% -254142 -26.73% 2018-06-30
Wells Capital Management Inc. 853825 1.03% 853825 -- 2018-06-30
Wells Fargo & Co 888768 1.07% 849233 2148.05% 2018-06-30
LFB Biotechnologies SA S U 2614855 3.17% -5000000 -65.66% 2018-07-06
State Street Corp 3712103 4.50% 593842 19.04% 2018-06-30
Franklin Advisers Inc 2263777 2.74% -128520 -5.37% 2018-06-30
Columbus Circle Investors 747285 0.91% -13745 -1.81% 2018-06-30
UBS Group AG 520596 0.67% -354175 -40.49% 2018-05-31
Goldman, Sachs & Co. 349572 0.42% 5544 1.61% 2018-06-30
Susquehanna Financial Group, LLLP 324631 0.42% -61125 -15.85% 2018-03-31
J.P. Morgan Investment Management Inc 285075 0.37% -256725 -47.38% 2018-03-31
Charles Schwab Investment Management Inc 268174 0.35% 1204 0.45% 2018-03-31
Susquehanna International Group, LLP 324631 0.42% -61125 -15.85% 2018-03-31
Kennedy Capital Management Inc 585439 0.80% 164210 38.98% 2017-12-31
University of Notre Dame Du Lac 302761 0.41% 302761 -- 2017-12-31
SENZAR ASSET MANAGEMENT, LLC 863500 1.22% -105800 -10.92% 2017-09-30
Artal Group S A 400000 0.57% -100000 -20.00% 2017-09-30
EAM Investors 308120 0.44% -5067 -1.62% 2017-09-30
Hikari Power Ltd 160000 0.23% 100000 166.67% 2017-09-30
Columbia Mangmt Investment Advisers, LLC 180451 0.26% -96284 -34.79% 2017-09-30
Credit Suisse First Boston (CSFB) 224066 0.32% 23514 11.72% 2017-09-30
Jennison Associates LLC 1243995 1.76% -106886 -7.91% 2017-09-30
Baker Bros Advisors LP 2003991 3.66% -- -- --
Eventide Asset Management, LLC 537600 0.98% -- -- --
Stoneridge Investment Partners LLC 289344 0.53% -6138 -2.08% --
New York State Common Retirement Fund 223851 0.41% -- -- --
UBS Asset Management (UK) Ltd 162870 0.30% 8081 5.22% --
Teachers Retirement System Of The State Of Kentucky 160700 0.29% -- -- --
Guggenheim Capital LLC 159879 0.29% -4334 -2.64% --
BlackRock Advisors LLC 148863 0.27% -4671 -3.04% --
LFB Biotechnologies, S.A.S. 7614855 4.00% 120619303 0.20% 1999-11-30
Michael S. Weiss 8389376 4.00% 132887716 0.20% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
iShares Micro-Cap ETF 200078 0.22% -- -- 2019-07-30
SPDR 3580868 3.94% 70072 2.00% 2019-07-31
Vanguard Total Stock Market Index Fund 2326090 2.56% -- -- 2019-06-30
iShares Russell 2000 ETF 1715255 1.89% 3355 0.20% 2019-07-30
Vanguard Extended Market Index Fund 1003112 1.10% 3881 0.39% 2019-06-30
Candriam Eqs L Biotechnology 692000 0.76% -- -- 2019-06-30
iShares Russell 2000 Growth ETF 650357 0.72% 12538 1.97% 2019-07-30
UBS (Lux) EF Biotech (USD) 564287 0.62% -- -- 2019-04-30
Highland Global Allocation Fund 387600 0.43% -- -- 2019-06-30
State Street Russell Small/Mid Cap 275039 0.30% -- -- 2019-06-30
State Street Russell Small Cap 263151 0.29% -- -- 2019-06-30
JPMorgan US Small Company Fund 208125 0.23% -11900 -5.41% 2019-06-30
Direxion Daily S&P Biotech Bull 3X Shrs 208434 0.23% 56548 37.23% 2019-04-30
NexPoint Strategic Opportunities Fund 210000 0.23% -- -- 2019-03-31
Schwab US Small-Cap ETF 216041 0.24% 184 0.09% 2019-07-31
NT R2000 Index Fund - NL 237282 0.26% 1424 0.60% 2019-06-30
Fidelity 256252 0.28% 32448 14.50% 2019-04-30
NT R2000 Growth Index Fund - Non-Lending 259924 0.29% -9271 -3.44% 2019-06-30
Vanguard Health Care Index Fund 197260 0.22% 23120 13.28% 2019-05-31
iShares US Small Cap ETF (CAD-Hedged) 1322274 1.46% -2223 -0.17% 2019-05-30
NT R2000 Growth Index Fund - Lending 183331 0.21% 592 0.32% 2019-03-31
Interfund Equity USA 197117 0.24% -102883 -34.29% 2019-02-28
Northern Trust Russell 2000 Index DC NL 164875 0.20% 9093 5.84% 2019-02-28
The Vanguard - Russell 2000 Grwth Idx CF 111946 0.13% -- -- 2019-01-31
Schwab Small Cap Index Fund 118841 0.14% -- -- 2019-01-31
Invesco Raymond James SB-1 Equity ETF 140954 0.17% -- -- 2018-10-12
AXA 2000 Managed Volatility Portfolio 102173 0.12% -- -- 2018-12-31
Fidelity Advisor 221296 0.27% -- -- 2018-11-30
Franklin Small Cap Growth Fund 253375 0.31% -333368 -56.82% 2018-10-31
Franklin Biotechnology Discovery Fund 347400 0.42% -156600 -31.07% 2018-10-31
Wells Fargo Discovery Fund 574500 0.69% -- -- 2018-08-31
PGIM Jennison Health Sciences Fund 938019 1.13% -- -- 2017-11-30
iShares Russell 2000 Growth 563937 0.59% -544 -0.10% 2018-09-12
Fidelity Spartan 115447 0.14% -- -- 2018-07-31
Vanguard Health Care ETF 123905 0.15% 1062 0.86% 2018-07-31
State Street Russell Small/Mid Cap Idx Fd Cl I 153665 0.23% 41364 36.83% 2017-06-30
Vanguard Total Stock Mkt Idx 1471915 1.78% -- -- 2018-07-31
Franklin Small Cap Growth A 842443 1.02% -- -- 2018-07-31
Vanguard Extended Market Idx Inv 806305 0.98% 23300 2.98% 2018-07-31
Wells Fargo Discovery Admin 574500 0.70% -- -- 2018-07-31
Franklin Biotechnology Discovery A 504000 0.61% -- -- 2018-07-31
JPMorgan US Small Company Instl 246300 0.30% 4800 1.99% 2018-07-31
NexPoint Credit Strategies Fund 210000 0.25% -- -- 2018-06-30
iShares Micro-Cap 157240 0.16% -- -- 2018-09-12
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 145078 0.18% -385 -0.26% 2018-07-31
Highland Global Allocation A 122600 0.15% -- -- 2018-06-30
Schwab Small Cap Index 110350 0.14% 17700 19.10% 2018-06-30
BlackRock Extended Equity Market K 102225 0.13% 27895 37.53% 2018-06-30
CREF Stock R1 87742 0.11% -- -- 2018-04-30
BioShares 91951 0.12% -- -- 2018-06-14
Guggenheim Raymond James SB-1 Equity ETF 87865 0.12% -- -- 2018-06-06
Vanguard Instl Ttl Stk Mkt Idx InstlPls 83701 0.11% -- -- 2018-03-31
The Vanguard Russell 2000 Growth Index 81786 0.11% -- -- 2018-03-31
Pru Ret Small Cap Value/Kennedy SP 130237 0.18% 33626 34.81% 2017-12-31
VP Partners Small Cap Growth 2 95639 0.14% -- -- 2018-01-31
Prudential Jennison Health Sciences A 938019 1.33% -- -- 2017-11-30
Eventide Healthcare & Life Sciences A 537600 0.98% -- -- --
AXA 2000 Managed Volatility K 57935 0.11% -- -- --
JNL/Mellon Capital Healthcare Sector B 33002 0.06% -- -- --
Nationwide HighMark Sm Cp Core A 54442 0.10% 1150 2.16% --
SPDR® S&P Biotech ETF 2007546 4.20% 13076 0.70% 2015-11-19
Fidelity Advisor® Biotechnology Fund 1328407 2.50% 54752 4.30% 2015-09-30
iShares Russell 2000 (AU) 560585 1.20% -708 -0.10% 2015-11-19
Eventide Healthcare & Life Sciences Fund 271100 0.50% 88100 48.10% 2015-06-30
Fidelity Spartan® Extended Mkt Indx Fd 143128 0.30% -- -- 2015-09-30
CREF Stock Account 91244 0.20% -- -- 2015-09-30
Alger Health Sciences Fund 80450 0.20% -- -- 2015-08-31
Fidelity® Select Biotechnology Portfolio 4629568 8.80% 230332 5.20% 2015-09-30

Michael Sean Weiss Mr. Michael S. Weiss is a Chairman at National Holdings Corp., a Chairman at Checkpoint Therapeutics, Inc., a Chairman at Mustang Bio, Inc., an Executive Chairman at IASO Pharma, Inc., a Partner at Opus Point Partners Management LLC, a Partner & Portfolio Manager at Opus Point Partners LLC and an Executive Chairman, President & CEO at TG Therapeutics, Inc. He is on the Board of Directors at Avenue Therapeutics, Inc., Caelum Biosciences, Inc., Cellvation, Inc., Cyprium Therapeutics, Inc. and Helocyte, Inc. Mr. Weiss began his professional career as a lawyer at Cravath, Swaine & Moore. From 1993 through 1999, he worked with Dr. Rosenwald in managing Paramount Capital/Aries Funds. In 1999, he founded Access Oncology which was later acquired by Keryx Biopharmaceuticals (NASDAQ: KERX) in 2004. Mr. Weiss earned his J.D. from Columbia Law School and his B.S. in Finance from The University at Albany.
Mark J. Schoenebaum Dr. Mark J. Schoenebaum, MD, is an Independent Director at TG Therapeutics, Inc. He is on the Board of Directors at Health Sciences Acquisitions Corp. and TG Therapeutics, Inc. Dr. Schoenebaum was previously employed as a Fundamental Research Analyst by Evercore Group LLC, a Senior Managing Director by International Strategy & Investment Group LLC, a Managing Director by Deutsche Bank Securities, Inc., a Senior Research Analyst by Bear, Stearns & Co., Inc., an Analyst by Alexandra Investment Management LLC, a Senior Research Analyst by Piper Jaffray & Co., and a Senior Analyst by CIBC World Markets Corp. (Old). He received his undergraduate degree from Indiana University and a doctorate degree from The Johns Hopkins University School of Medicine.
William James Kennedy William James Kennedy is on the board of TG Therapeutics, Inc. In his past career he held the position of Vice President-Regulatory Affairs at Zeneca Corp. and Associate Research Professor at Yale School of Medicine. Dr. Kennedy received an undergraduate degree from Siena College, a graduate degree from Clark University and a doctorate from State University of New York at Buffalo.
Laurence N. Charney Mr. Laurence N. Charney is an Independent Director at Kenon Holdings Ltd., an Independent Director at TG Therapeutics, Inc., a Member at New York State Society of Certified Public Accountants and a Member at The American Institute of Certified Public Accountants. He is on the Board of Directors at Kenon Holdings Ltd. and TG Therapeutics, Inc. Mr. Charney was previously employed as an Independent Director by IC Power Ltd. (Singapore), an Independent Director by Pacific Drilling SA, an Independent Director by Iconix Brand Group, Inc., a Director-Americas by Conflict Management Group, and a Senior Audit Partner by Ernst & Young LLP. He also served on the board at Mrs. Fields' Original Cookies, Inc., Pure Biofuels Corp., XTL Biopharmaceuticals Ltd. and Marvel Entertainment LLC. He received his undergraduate degree from Hofstra University and an MBA from Columbia University.
Jenna A. Bosco Presently, Jenna A. Bosco is Senior Vice President-Corporate Communications at TG Therapeutics, Inc. In her past career she held the position of Principal at Opus Point Partners Management LLC. Ms. Bosco received an undergraduate degree from Robert H. Smith School of Business.
Jenna A. Bosco Presently, Jenna A. Bosco is Senior Vice President-Corporate Communications at TG Therapeutics, Inc. In her past career she held the position of Principal at Opus Point Partners Management LLC. Ms. Bosco received an undergraduate degree from Robert H. Smith School of Business.
Sean A. Power Currently, Sean A. Power is Chief Financial Officer, Secretary & Treasurer for TG Therapeutics, Inc. He is also Member of The American Institute of Certified Public Accountants. In his past career he occupied the position of Chief Financial Officer for Opus Point Partners Management LLC, Associate of UHY Advisors, Inc., Senior Associate at KPMG, Inc. and Controller at Keryx Biopharmaceuticals, Inc. He received an undergraduate degree from Siena College.
Kenneth Hoberman Presently, Kenneth Hoberman is Chief Operating Officer & Secretary at Stemline Therapeutics, Inc. Mr. Hoberman is also on the board of TG Therapeutics, Inc. In the past he held the position of Vice President-Business Development of Keryx Biopharmaceuticals, Inc. Mr. Hoberman received an undergraduate degree from Boston University.
Robert Niecestro Dr. Robert Niecestro is Vice President-Clinical & Regulatory at Axsome Therapeutics, Inc. and Executive Vice President-Clinical & Regulatory at TG Therapeutics, Inc. Dr. Niecestro was previously employed as Vice President-Clinical Development by Andrx Laboratories, Inc., Senior Director-Clinical Development by Eisai, Inc., Vice President-Clinical & Regulatory Affairs by Keryx Biopharmaceuticals, Inc., and Director-Clinical Operations by Organon USA, Inc. He received his undergraduate degree from the University of Illinois.
Yann Echelard Yann Echelard is on the board of TG Therapeutics, Inc., LFB USA, Inc. and Hema Biologics. In the past he was President, Chief Executive Officer & Director at rEVO Biologics, Inc., Vice President-Research & Development at GTC Biotherapeutics UK Ltd. and Principal at rEVO Biologics, Inc. He received a doctorate from the University of Montr�0�1�0�8al.
Daniel Hume Daniel Hume is on the board of TG Therapeutics, Inc., National Holdings Corp. and Stemline Therapeutics, Inc. and Member of New York State Bar Association, Partner at Kirby Mcinerney LLP and Member of Supreme Court of the United States. He received an undergraduate degree from State University of New York at Albany and a graduate degree from Columbia Law School.
Adam Waldman Adam Waldman is Chief Commercial Officer of TG Therapeutics, Inc. In the past he held the position of Head-Haematology & Oncology Marketing at Celgene Corp. Mr. Waldman received an MBA from the University of Rochester Simon Business School and an undergraduate degree from Rutgers State University of New Jersey.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐